Our Blog discusses the development of rejuvenation biotechnology around the world: progress being made in the field of longevity, the design of medical therapies to cure, reverse and prevent the diseases and disabilities of aging, and much more.
Our content is a blend of popular interest articles – labelled “Easy Reads”, and designed to require no specific background knowledge – as well as more detailed scientific commentaries, labelled as “In-Depth” and aimed towards readers with some grounding in the biological/medical sciences.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In the final installment of this 5-part series, we look at TAME itself: how it’s structured, how it’s justified, and how the results could impact the push for longevity therapeutics.
A supporter asks us to elaborate on projects other than allotopic expression (AE), that SRF has undertaken that are targeting mitochondrial dysfunction; and how they relate to the original strategy of allotopic expression?
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 4 of this 5-part series, we look at human data on metformin and neurodegenerative aging diseases.
A supporter asks about the investigative report in Science magazine that suggests the critical study identifying beta-amyloid oligomers as the key actors in Alzheimer’s disease may have been based on fraudulent data.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 3 of this 5-part series, we look at human trials of metformin in prevention and treatment of cancer.
A supporter asks about how the central MitoSENS strategy can be delivered to our cells.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
